Relative Bioavailability of Single Doses of Dabigatran Etexilate in Healthy Volunteers
- Registration Number
- NCT02173717
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
Study to investigate whether and to what extent the suggested P-glycoprotein (P-gp) inducer rifampicin affects plasma exposure of dabigatran.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
- Healthy male or female subjects according to the following criteria: based upon a complete medical history, including the physical examination, vital signs (BP, pulse rate), 12-lead ECG, clinical laboratory tests
- Age ≥18 and Age ≤45 years
- Body Mass Index (BMI) ≥18.5 and ≤29.9 kg/m2
- Signed and dated written informed consent prior to admission to the study in accordance with GCP and the local legislation
Exclusion Criteria
-
Any gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, or hormonal disorders
-
Subjects who in the investigator's judgement were perceived as having an increased risk of bleeding, for example because of:
- Hemorrhagic disorders or bleeding diathesis
- Occult blood in faeces or haematocryal
- Trauma or surgery within the last month or as long as an excessive risk of bleeding persisted after these events, or planned surgery during trial participation
- History of arteriovenous malformation or aneurysm
- History of gastroduodenal ulcer disease, gastrointestinal haemorrhage, and haemorrhoids
- History of intracranial, intraocular, spinal, retroperitoneal, or atraumatic intraarticular bleeding
- Use of drugs that may have interfered with haemostasis during trial conduct (e.g. acetylic salicylic acid or other non-steroidal anti-inflammatory drugs)
- Relevant surgery of gastrointestinal tract
-
Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
-
History of relevant orthostatic hypotension, fainting spells, or blackouts
-
Chronic or relevant acute infections
-
History of allergy/hypersensitivity (including drug allergy) which was deemed relevant to the trial as judged by the investigator
-
Use of drugs which might have reasonably influenced the results of the trial based on the knowledge at the time of protocol preparation within four weeks prior to administration or during the trial, especially inhibitors or inducers of P-gp, CYP3A4, CYP2C9, or CYP2C19 trial (comment: CYP3A4 inhibitors are for example azole antimycotics, macrolides or grapefruit juice, CYP3A inducers are for example St. John's Wort or certain anticonvulsants)
-
Intake of medication, which influences the blood clotting, i.e. acetylsalicylic acid, nonsteroidal anti-rheumatic drugs, cumarin, etc. within 14 days prior to screening or during the trial
-
Participation in another trial with an investigational drug within one month prior to administration or during the trial
-
Alcohol abuse (more than 60 g/day in males, more than 40 g/day in females)
-
Drug abuse
-
Blood donation (more than 100 mL within 4 weeks prior to administration)
-
Any laboratory value outside the reference range that was of clinical relevance
-
Inability to comply with dietary regimen of study centre
-
Previous intake of rifampicin
-
For female subjects:
- Pregnancy / positive pregnancy test, or planning to become pregnant during the study or within 1 month of study completion
- No adequate contraception in women of childbearing potential
- Lactation period
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Dabigatran etexilate Dabigatran etexilate Four treatments of 150 mg Dabigatran etexilate (single oral administration) in a fixed sequence. 1. Single oral administration of dabigatran etexilate on Day 1; 2. Oral administration of 600 mg rifampicin q.d. in the evening for 7 days (Days 2 to 8) followed by an oral morning dose of dabigatran etexilate on Day 9; 3. Single oral administration of dabigatran etexilate on Day 16, after 7 days of rifampicin washout; 4. Single oral administration of dabigatran etexilate on Day 23, after 14 days of rifampicin washout Dabigatran etexilate Rifampicin Four treatments of 150 mg Dabigatran etexilate (single oral administration) in a fixed sequence. 1. Single oral administration of dabigatran etexilate on Day 1; 2. Oral administration of 600 mg rifampicin q.d. in the evening for 7 days (Days 2 to 8) followed by an oral morning dose of dabigatran etexilate on Day 9; 3. Single oral administration of dabigatran etexilate on Day 16, after 7 days of rifampicin washout; 4. Single oral administration of dabigatran etexilate on Day 23, after 14 days of rifampicin washout
- Primary Outcome Measures
Name Time Method Maximum measured concentration (Cmax) of total dabigatran 30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 334hours after treatment on Day1, 9, 16 and 23 Area under the concentration-time curve over the time interval from 0 extrapolated to infinity (AUC0-inf) of total dabigatran 30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23
- Secondary Outcome Measures
Name Time Method Cmax of dabigatran etexilate 30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23 AUC0-inf of free dabigatran 30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23 Cmax of free dabigatran 30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23 Time from dosing to the maximum concentration (tmax) of dabigatran etexilate 30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23 Cmax of BIBR 1087SE 30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23 tmax of BIBR 1087SE 30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23 Cmax of BIBR 951BS 30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23 tmax of free dabigatran 30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23 tmax of total dabigatran 30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23 tmax of BIBR 951BS 30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23 Area under the concentration-time curve over the time interval from 0 to the time of the last quantifiable data point (AUC0-tz) of free dabigatran 30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23 AUC0-tz of total dabigatran 30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23 Area under the concentration-time curve over the time interval from timepoints t1 to t2 (AUCt1-t2) of free dabigatran 30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23 AUCt1-t2 of total dabigatran 30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23 Area under the concentration-time curve over the time interval from 0 to 24 h (AUC0-24) of free dabigatran 30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23 AUC0-24 of total dabigatran 30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23 Terminal rate constant (λz) of free dabigatran 30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23 λz of total dabigatran 30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23 Terminal half-life (t1/2) of free dabigatran 30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23 t1/2 of total dabigatran 30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23 Mean residence time after oral administration (MRTpo) of free dabigatran 30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23 MRTpo of total dabigatran 30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23 Apparent clearance after extravascular administration (CL/F) of free dabigatran 30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23 CL/F of total dabigatran 30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23 Apparent volume of distribution during the terminal phase λz following an extravascular dose (Vz/F) of free dabigatran 30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23 Vz/F of total dabigatran 30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23 Amount that is eliminated in urine from the time interval 0- 24h (Ae0-24) of total dabigatran Day 1 and 9 Fraction excreted unchanged in urine from time point 0-24h (fe0-24) of total dabigatran Day 1 and 9 Renal clearance from the time point 0 until the point 0-24h (CLR, 0-24) of total dabigatran Day 1 and 9 Ratio of 6-ß-hydroxycortisol/cortisol in morning spot urine as a marker of CYP 3A induction Day 1 and 9